Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among
HIV-infected persons--2002. Recommendations of the US Public Health Service and the
Infectious Diseases Society of America. Ann Intern Med. 2002;137(5 Pt 2):435478.
Mathews G, Bhagani S. The epidemiology and natural history of HIV/HBV and HIV/HCV co-
infections. J HIV Ther. 2003;8:7784.
Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies: an
international perspective. Hematol Oncol Clin North Am. 2003;17:673696.
Milinkovic A, Martinez E. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther.
2004;2:367373.
Patel N, Koziel H. Pneumocystis jiroveci pneumonia in adult patients with AIDS: treatment
strategies and emerging challenges to antimicrobial therapy. Treat Respir Med.
2004;3:381397.
Sankatsing SU, Weverling GJ, Peeters M, et al. TMC125 exerts similar initial antiviral potency as
a five-drug, triple class antiretroviral regimen. AIDS. 2003;17:26232627.
Smith HV, Corcoran GD. New drugs and treatment for cryptosporidiosis. Curr Opin Infect Dis.
2004;17:557564.
Turpin JA. The next generation of HIV/AIDS drugs: novel and developmental anti-HIV drugs
and targets. Expert Rev Anti Infect Ther. 2003;1:97128.
UNAIDS 2004 report on the global AIDS epidemic. Joint United Nations Programme on
HIV/AIDS. Available at http://www.unaids.org/bangkok2004/report.html. Accessed
March?1, 2005.
Wang LH, Begley J, St Claire RL 3rd, et al. Pharmacokinetic and pharmacodynamic
characteristics of emtricitabine support its once daily dosing for the treatment of HIV
infection. AIDS Res Hum Retroviruses. 2004;20:11731182.
Wensing AM, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev.
2003;5:140155.
Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J Acquir
Immune Defic Syndr. 2003;34 suppl 1:S9194.
Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in
2002: updated recommendations of the International AIDS Society--USA Panel. JAMA.
2002;288:222235.
Antibiyotiklerde Güncel Geliflmeler
Yar>m yüzy>ld>r, enfeksiyon hastal>klar>n>n yönetiminde ana e¤ilim antibiyotik tedavisi-
nin gelifltirilmesi ve saflaflt>r>lmas> olmufltur. Yeni antibiyotiklerin gelifltirilmesini teflvik
eden faktörler dirençli bakteri sufllar>, ekonomi ve istenmeyen yan etkilerin yok edilmesi
iste¤idir. Son iki yüzy>ld>r, a¤>rl>k aminoglikozidlerden
-laktamlara ve karbapenem ve mono-
baktamlar gibi yeni antibiyotik s>n>flar>n> gelifltirmeye kaym>flt>r. Ek olarak vankomisin,
TMP-SMX, eritromisin ve rifampin genifl bir kullan>m alan> bulmufltur. Kinolonlar ciddi en-
feksiyonlar> hastane d>fl> olarak tedavi edebilme olas>l>¤>n> sa¤lam>flt>r. Asiklovir, gansiklo-
vir, zidovudin ve ribavirin gibi antiviral ilaçlar>n hepsi viral DNA polimeraz> (revers trans-
kriptaz>) engelleyen ve uzayan viral DNA zincirini kesen nükleozid analo¤udur. Ek olarak
sistemik mantar enfeksiyonlar>n>n tedavisi için birkaç yeni imidazol bilefli¤i de takdim
edilmifltir.
Bölüm 1:
Enfeksiyon Hastal>klar>
·
53